Opternative Sues Warby Parker Over Online Eye Exams

November 10, 2017: By Jon Swedien

legal issuesOpternative, the Chicago-based online vision test company, has filed a lawsuit against online eyewear retailer Warby Parker. The suit follows Warby Parker’s launch of a competing online vision test.

In the suit, filed Oct. 16, Opternative said Warby Parker breached nondisclosure agreements and misappropriated trade secrets when it launched its online eye exam in May 2017. Opternative launched its online eye exam in 2015.

In 2013, when Opternative was still developing its test, the company had discussions with Warby Parker about a potential partnership and possibly an acquisition by Warby Parker of Opternative.

During those discussions, Opternative said it required Warby Parker to sign nondisclosure agreements as it shared proprietary information. Opternative alleges Warby Parker violated those agreements in creating an online eye exam that is derivative of its own.

No partnership or acquisition was ever agreed to among the companies.

“Despite assurances to the contrary, Warby Parker had already developed an intent to develop its own online eye exam system, even as it negotiated for unfettered access to the inner workings of Opternative’s system,” the suit states.

Warby Parker has filed a motion to dismiss the lawsuit. In its motion to dismiss, Warby Parker said Opternative’s suit fails to show similarities between the two eye exams and the information Opternative shared was “limited, nontechnical information.”

“This action is an attempt by the plaintiff to recover through the courts where it has failed in the marketplace,” Warby Parker said in the motion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022